CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
SOM230Cdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00859040
NCT00859040Phase 2Completed
CompareCT.gov

Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma

Patrick Y. Wen, MD·interventional·Posted Mar 10, 2009·Updated Oct 27, 2017

In Brief

A Phase 2 clinical trial evaluating SOM230C for Meningioma. Completed, enrolled 34 participants across 8 sites.

Detailed Summary

The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those other research studies suggests that SOM230C may help to stop the growth of meningiomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningioma
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center, Wake Forest University Health Sciences, Duke University, Cedars-Sinai Medical Center, Northwestern University, Novartis

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2009
Enrollment StartMar 1, 2009
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.3 years ago

Interventions

SOM230Cdrug

Injection in the buttocks every 28 days